BR112022000382A2 - Administração de agonista de sting e inibidores de checkpoint - Google Patents

Administração de agonista de sting e inibidores de checkpoint

Info

Publication number
BR112022000382A2
BR112022000382A2 BR112022000382A BR112022000382A BR112022000382A2 BR 112022000382 A2 BR112022000382 A2 BR 112022000382A2 BR 112022000382 A BR112022000382 A BR 112022000382A BR 112022000382 A BR112022000382 A BR 112022000382A BR 112022000382 A2 BR112022000382 A2 BR 112022000382A2
Authority
BR
Brazil
Prior art keywords
checkpoint inhibitors
administration
sting agonists
need
sting
Prior art date
Application number
BR112022000382A
Other languages
English (en)
Inventor
Scott Lightcap Eric
Yosuke Sato
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of BR112022000382A2 publication Critical patent/BR112022000382A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

administração de agonista de sting e inibidores de checkpoint. a presente divulgação fornece métodos, composições farmacêuticas e kits para o tratamento de câncer em pacientes em necessidade. os métodos compreendem a administração a um paciente em necessidade de um agonista de sting (estimulador de genes de interferon), como o composto n° 14, conforme definido na descrição, ou um sal farmaceuticamente aceitável deste em combinação com um ou mais inibidores de checkpoint. também são fornecidos medicamentos para uso no tratamento do câncer.
BR112022000382A 2019-07-09 2020-07-09 Administração de agonista de sting e inibidores de checkpoint BR112022000382A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962872039P 2019-07-09 2019-07-09
US201962944650P 2019-12-06 2019-12-06
US202062994911P 2020-03-26 2020-03-26
PCT/IB2020/056440 WO2021005541A1 (en) 2019-07-09 2020-07-09 Administration of sting agonist and checkpoint inhibitors

Publications (1)

Publication Number Publication Date
BR112022000382A2 true BR112022000382A2 (pt) 2022-03-03

Family

ID=71614932

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022000382A BR112022000382A2 (pt) 2019-07-09 2020-07-09 Administração de agonista de sting e inibidores de checkpoint

Country Status (11)

Country Link
US (1) US20220257630A1 (pt)
EP (1) EP3996718A1 (pt)
JP (1) JP2022540605A (pt)
KR (1) KR20220029651A (pt)
CN (1) CN114080228A (pt)
AU (1) AU2020309837A1 (pt)
BR (1) BR112022000382A2 (pt)
CA (1) CA3146490A1 (pt)
MX (1) MX2022000430A (pt)
TW (1) TW202116330A (pt)
WO (1) WO2021005541A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7195317B2 (ja) 2017-11-10 2022-12-23 武田薬品工業株式会社 Ｓｔｉｎｇ調節剤化合物、ならびに製造及び使用する方法
AU2021383424A1 (en) * 2020-11-18 2023-06-08 Takeda Pharmaceutical Company Limited Administration of sting agonist, checkpoint inhibitors, and radiation
WO2022223619A1 (en) 2021-04-20 2022-10-27 Institut Curie Compositions and methods for use in immunotherapy
WO2022223622A1 (en) 2021-04-20 2022-10-27 Institut Curie Compositions and methods for use in immunotherapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114835812A (zh) 2008-12-09 2022-08-02 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
EP3371221A2 (en) * 2015-11-07 2018-09-12 MultiVir Inc. Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
WO2018112360A1 (en) * 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating cancer
RU2019122602A (ru) * 2016-12-20 2021-01-22 Мерк Шарп И Доум Корп. Комбинации антагонистов pd-1 и циклических динуклеотидных агонистов sting для лечения рака
JP2020529421A (ja) * 2017-08-04 2020-10-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． がんの処置のためのＰＤ−１アンタゴニストおよびベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニストの組み合わせ

Also Published As

Publication number Publication date
AU2020309837A1 (en) 2022-02-24
EP3996718A1 (en) 2022-05-18
JP2022540605A (ja) 2022-09-16
KR20220029651A (ko) 2022-03-08
TW202116330A (zh) 2021-05-01
WO2021005541A1 (en) 2021-01-14
CA3146490A1 (en) 2021-01-14
MX2022000430A (es) 2022-04-25
CN114080228A (zh) 2022-02-22
US20220257630A1 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
BR112022000382A2 (pt) Administração de agonista de sting e inibidores de checkpoint
ES2653615T3 (es) Pluralidad de dosis de LAG-3 recombinante para su uso en la provocación de una respuesta inmunitaria de monocitos
Henke et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial
BR112014028633A8 (pt) tratamento de amd usando sflt-1 de aav
BR112023018785A2 (pt) Composto cíclico fundido com pirimidina, método de preparação do mesmo e uso do mesmo
BR112012018500A2 (pt) alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
BR112015026006A8 (pt) composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
AR109103A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112015022896A2 (pt) drogas de alta penetração e suas composições para o tratamento de doenças de parkinson
RU2017132877A (ru) Комбинация антагониста pd-1 и эрибулина для лечения рака
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
MX2021009199A (es) Conjugado de farmaco de dos ligandos y uso del mismo.
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
BR112017019343A2 (pt) uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas
BR112021024886A2 (pt) Métodos de tratar a doença de fabry em pacientes com insuficiência renal
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
WO2018005801A3 (en) Novel non-systemic tgr5 agonists
BR112023000270A2 (pt) Composto, composição farmacêutica, e, peptídeo
BR112021006318A2 (pt) terapia de combinação para o tratamento de câncer
BR112012020185A2 (pt) uso de preparações de heparina oral para tratar doenças e afecções do trato urinário.